Drug Trial Radar · NCT06757335
A Phase I/II Trial to Evaluate Oral HP568 Tablets in Patients with ER+/HER2 Advanced Breast Cancer
Last checked: Nov 19, 2026Latest source record: Jan 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
204
Planned (sponsor's estimate)
Start
Jan 7, 2025
Primary completion
Jan 31, 2026
Study completion Nov 27, 2026
Sponsor
- Lead sponsor
- Hinova Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/2 dose escalation and cohort expansion study and will assess the safety, tolerability and preliminary efficacy of HP568 alone and in combination with palbociclib in patients with ER+/HER2- locally advanced or metastatic breast cancer.
Conditions
- Breast Cancer
Interventions
HP568Drug
In the I/II stage: HP568 administered QD or BID for 28 day cycles.
HP568 in combination with palbociclibDrug
In the III stage: Daily oral dosages of HP568 for 28 days in combination with palbociclib for 21 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Stage I: the incidence of TEAE of HP568Time frame: From the first administration dose to 30 calendar days after the last administration dose
- Stage I: Incidence of dose limiting toxicity DLT, maximum tolerated dose MTD (if possible).Time frame: 28 days
- Stage III: Evaluate safety during the dose escalation phase of combination therapyTime frame: From the first administration dose to 30 calendar days after the last administration dose
- Stage III: Evaluate tolerance during the dose escalation phase of combination therapyTime frame: 28 days
- Stage III: Evaluate the 24 week clinical benefit rate (CBR) during the dose escalation phase of combination therapyTime frame: Until all patients have completed 24 weeks administration
- Stage II: 24 week clinical benefit rate (CBR)Time frame: Until all patients have completed 24 weeks administration
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.